作者: I J Dunkel , J M Boyett , A Yates , M Rosenblum , J H Garvin
DOI: 10.1200/JCO.1998.16.1.222
关键词: Autologous Stem Cell Rescue 、 Carboplatin 、 Medicine 、 Etoposide 、 Recurrent Medulloblastoma 、 Transplantation 、 Surgery 、 ThioTEPA 、 Chemotherapy 、 Hematopoietic stem cell transplantation
摘要: PURPOSEMedulloblastoma is a highly lethal disease when it recurs. Very few patients survive with conventional treatment. This study evaluated the use of high-dose carboplatin, thiotepa, and etoposide autologous stem-cell rescue (ASCR) in recurrent medulloblastoma.METHODSChemotherapy consisted carboplatin 500 mg/m2 (or area under curve = 7 mg/mL x min via Calvert formula) on days -8, -7, -6; thiotepa 300 250 -5, -4, -3; followed by ASCR day 0. In addition to study-prescribed therapy, 21 received other treatment: neurosurgical resection seven, chemotherapy 17, external-beam irradiation 11 cases.RESULTSTwenty-three medulloblastoma, aged two 44 years (median, 13 years) at ASCR, were treated. Three died treatment-related toxicities within ASCR; multiorgan system failure two, Aspergillus infection venoocclusive one. Seven 23...